RxDoctor Payments Data

Sumit Kalra, MD

Cardiovascular Disease · Matthews, NCNPI 1497941025

Payments from drug & device makers

$2,428in general payments, 2019–2025

Across 81 payments — averaging $29.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$397
  • Boston Scientific$396
  • Amgen$372
  • Novartis$221
  • Johnson & Johnson$155
  • Edwards Lifesciences$143
  • plus $745 from 13 others

What the payments were for

  • Food & beverage$2,428100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,428 in reported general payments places this provider in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$173,614
Medicare patients
1,007
Services billed
2,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban412$428,456
JardianceEmpagliflozin135$141,029
EntrestoSacubitril/Valsartan116$107,294
Repatha SureclickEvolocumab92$65,046
FarxigaDapagliflozin Propanediol85$57,219
XareltoRivaroxaban34$38,806
MultaqDronedarone Hcl13$10,645
Flecainide Acetate86$4,492
Rosuvastatin Calcium322$3,298
Metoprolol Succinate222$2,411
Nitroglycerin26$1,943
Atorvastatin Calcium157$1,667
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$1,582
Amlodipine Besylate226$1,223
Amiodarone Hcl43$1,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$428,456412 claims
Boehringer IngelheimJardiance$25$141,029135 claims
NovartisEntresto$221$107,294116 claims
AstraZenecaFarxiga$111$57,21985 claims
Johnson & JohnsonXarelto$155$38,80634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →